XML 74 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Results of Operations (Unaudited)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Results of Operations (Unaudited) Quarterly Results of Operations (Unaudited)

The following table summarizes unaudited quarterly financial data:
 
Three Months Ended
 ($ in thousands, except for per share amounts)
December 31, 2019
 
September 30, 2019
 
June 30, 2019
 
March 31, 2019
Consolidated Statements of Comprehensive Loss Data:
 
 
 
 
    
 
    
Revenues
$
295

 
$
—

 
$
—

 
$
—

Net loss attributable to Immunomedics, Inc. stockholders
$
(99,608
)
 
$
(94,292
)
 
$
(75,953
)
 
$
(87,337
)
Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted)
$
(0.50
)
 
$
(0.49
)
 
$
(0.40
)
 
$
(0.46
)
Weighted average shares used to calculate loss per common share – (basic and diluted)
199,614

 
191,981

 
191,745

 
191,052


 
Three Months Ended
 ($ in thousands, except for per share amounts)
December 31, 2018
 
September 30, 2018
 
June 30, 2018
 
March 31, 2018
Consolidated Statements of Comprehensive Loss Data:
 
 
 
 
    
 
    
Revenues
$
—

 
$
—

 
$
387

 
$
482

Net loss attributable to Immunomedics, Inc. stockholders
$
(93,499
)
 
$
(64,169
)
 
$
(117,032
)
 
$
(35,546
)
Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted)
$
(0.50
)
 
$
(0.34
)
 
$
(0.68
)
 
$
(0.21
)
Weighted average shares used to calculate loss per common share – (basic and diluted)
190,171

 
186,937

 
171,124

 
166,054